Rimedio Pharma Private Limited
About Rimedio Pharma Private Limited
Data last updated:
Rimedio Pharma Private Limited was a private limited company based in Mumbai, Maharashtra, India, operated as a subsidiary of Entero Healthcare Solutions Private Limited. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 26 March 2020.
The company was registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2020PTC339123.
The company had an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It was led by directors including Kaushik Balakrishnan Natesan and Prashant Paleja.
Its last annual general meeting (AGM) was held on 28 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office was at Unit No. 605/606 6th Floor Trade Centre Bandra Kurla Complex Bandra East Mumbai, Maharashtra, India – 400051.
Company details
Contact details
Rimedio Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressUnit No. 605/606 6th Floor Trade Centre Bandra Kurla Complex Bandra East Mumbai, Maharashtra, India – 400051
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Rimedio Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Rimedio Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Rimedio Pharma Private Limited, buy the company report.
Financials of Rimedio Pharma Private Limited
FY 2024 filings availableFinancial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ||||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ||||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | ||||
| Net Profit Margin | ||||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Rimedio Pharma Private Limited, buy the company report.
Board of directors of Rimedio Pharma Private Limited
Rimedio Pharma has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kaushik Balakrishnan Natesan Also directs: Curever Pharma Private Limited | Director | 26 Mar 2020 | 6 Years 6 Months | As last reported |
| Satyendra Tiwari | Additional Director | 10 Feb 2025 | 1 Years 8 Months | As last reported |
| Prashant Paleja | Director | 16 Aug 2023 | 3 Years 2 Months | As last reported |
Auditor
Rimedio Pharma Private Limited is audited by PRATAP B. SHETH & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PRATAP B. SHETH & CO. | FY 2023 | 108140W |
Shareholding
The shareholding of Rimedio Pharma Private Limited is on record for 2 financial years, the latest being FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2022 | FY 2021 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Rimedio Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Rimedio Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Rimedio Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Rimedio Pharma Private Limited has 1 active EPFO establishment as of Apr 04, 2024.
GST
No GST registration is on our record for Rimedio Pharma Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Rimedio Pharma Private Limited has 11 board changes on record since 2020: 7 appointments and 4 cessations. The latest: Amit Mangilal Bishnoi ceased to be Director on 10 Feb 2025.
2 earlier events are in the company report.
Frequently asked questions
Rimedio Pharma has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Rimedio Pharma was a private limited company based in Mumbai, Maharashtra, India. The company worked in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 26 March 2020 and is registered under CIN U51909MH2020PTC339123. The company has been struck off by the Registrar of Companies and is no longer operational.
Rimedio Pharma had 3 directors:
- Kaushik Balakrishnan Natesan - Director
- Satyendra Tiwari - Additional Director
- Prashant Paleja - Director
The CIN (Corporate Identification Number) of Rimedio Pharma is U51909MH2020PTC339123. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Rimedio Pharma is at Unit No. 605606 6th Floor Trade Centre Bandra Kurla Complex Bandra East Mumbai, Maharashtra, India – 400051.
Rimedio Pharma was incorporated on 26 March 2020. It is registered with the Registrar of Companies, Mumbai.
The latest financial statements of Rimedio Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 28 September 2024. Year-wise statements from FY 2020 are in the company report.
Rimedio Pharma operated in the pharma industry, in the pharmaceutical retailers and distributors segment. It worked in this industry before it was struck off.
Amit Mangilal Bishnoi ceased to be Director on 10 Feb 2025. Satyendra Tiwari was appointed as Additional Director on 10 Feb 2025. Akshay Jain ceased to be Additional Director on 26 Feb 2024. Rimedio Pharma has 11 board changes on record in total.
Rimedio Pharma can be reached at its registered office: Unit No. 605606 6th Floor Trade Centre Bandra Kurla Complex Bandra East Mumbai, Maharashtra, India – 400051.